Amryt Pharma PLC - Draft registration statement for US Nasdaq listing
| || |
("Amryt" or the "Company")
Amryt submits draft registration statement for US listing on the Nasdaq
Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and developing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces today that it has confidentially submitted a draft registration statement on Form F-1 to the
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued in accordance with Rule 135 under the Securities Act.
Certain statements contained in this press release constitute "forward-looking statements." These forward-looking statements represent the Company's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These statements include, but are not limited to, statements regarding the pursuit of the potential
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014.
| || |
+353 (1) 518 0200
| || |
This information is provided by RNS, the news service of the
Quick facts: Amryt Pharma PLC
Market Cap: £268.83 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE